Hypopigmentation, Vitiligo, and Melanoma: New Data, More Enigmas

Archives of Dermatology

Volumn 123, Issue 8, 1987, Pages 1005-1008

  Nordlund, James J ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EDITORIAL; HUMAN; HYPOPIGMENTATION; MELANOMA; NONHUMAN; PRIORITY JOURNAL; VITILIGO;

ANIMAL; HUMAN; MELANOCYTES; MELANOMA; MELANOMA, EXPERIMENTAL; PIGMENTATION DISORDERS; SKIN; SKIN NEOPLASMS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; VITILIGO;

EID: 0023262947     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archderm.1987.01660320047009     Document Type: Article

References (21)

1. Nordlund JJ, Kirkwood JM, Forget BM, et al: Vitiligo in patients with metastatic melanoma: A good prognostic sign. J Am Acad Dermatol 1983;9:689–696.
2. Koh HK, Sober AJ, Nakagawa H, et al: Malignant melanoma and vitiligo-like leukoderma: An electron microscopic study. J Am Acad Dermatol 1983;9:696–708.
3. Lerner AB, Nordlund JJ: Should vitiligo be induced in patients after resection of primary melanoma? Arch Dermatol 1977;113:421.
4. Rigel DS, Rogers GS, Friedman RJ, et al: Prognosis in malignant melanoma. Derm Clin North Am 1985;3:309–314.
5. Lerner AB, Nordlund JJ: Vitiligo: Its status in 1980, in Seiji M (ed): Phenotypic Expression in Pigment Cells. Tokyo, University of Tokyo Press, 1981.
6. Lerner AB, Shiohara T, Boissy RE, et al: A mouse model for vitiligo. J Invest Dermatol 1986;87:299–304.
7. Hook RR Jr, Berkelhammer J, Oxenhandler RW: Animal model of human disease: Melanoma: Sinclair swine melanoma. Am J Pathol 1982;108:130–133.
8. Oxenhandler RW, Berkelhammer J, Smith GD, et al: Growth and regression of cutaneous melanomas in Sinclair miniature swine. Am J Pathol 1982;109:259–269.
9. Nordlund JJ, Gershon R: Splenic regulations of the clinical appearance of small tumors. J Immunol 1975;114:1486–1490.
10. Nordlund JJ, Ackles AE, Gershon RK: Quantitative factors which determine the effect of the immune response on the growth rate of the Cloudman melanoma in the DBA/2 mice. Cell Immunol 1980;56:258–272.
11. Laucius JF, Mastrangelo MJ: Cutaneous depigmentary phenomena in patients with malignant melanoma, in Clark WH Jr, Goldman LI, Mastrangelo MJ (eds): Human Malignant Melanoma. New York, Grune & Stratton, 1979, pp 209–225.
12. Lerner AB, Kirkwood JM: Vitiligo and melanoma: Can genetically abnormal melanocytes result in both vitiligo and melanoma within a single family? J Am Acad Dermatol 1984;11:696–701.
13. Nicholls EM: Development and elimination of pigmented moles, and the anatomical distribution of primary malignant melanoma. Cancer 1973;32:191–195.
14. Nordlund JJ, Kirkwood JM, Forget BM, et al: A demographic study of clinically atypical (dysplastic) nevi in patients with melanoma and comparison subjects. Cancer Res 1985;45:1855–1861.
15. Bookstein R, Halaban R, Shaw H, et al: Analysis of natural antibody to cultured human melanoma and melanocytes. Clin Res 1983;31:403.
16. Naughton GK, Eisinger M, Bystryn J-C: Antibodies to melanocytes in vitiligo. J Exp Med 1983;158:246–251.
17. Bystryn J-C, Naughton GK: Immunity to pigmented cells in vitiligo and melanoma. Fed Proc 1984;43:1663.
18. Moellman GE, Krass PH, Halaban R, et al: On the subject of serum antibodies on melanocytes in vitiligo. J Invest Dermatol 1985;84:333.
19. Norris DA, Kissinger RM, Bystryn J-C, et al: A profile of cytotoxic damage to human melanocytes produced by vitiligo patients' sera in vitro, abstracted. J Invest Dermatol 1986;87:439A.
20. Norris DA, Bystryn J-C, Kissinger RM: Direct evidence for immunologic cytotoxicity as a mechanism of human vitiligo, abstracted. Clin Res 1987;35:251A.
21. Feeney-Burns L, Alspaugh M, Burns RP, et al: Uveitis in melanomatous swine: Lack of evidence for humoral immune melanocyte destruction. Invest Ophthalmol Vis Sci 1985;26:551–560.